Analysis of microvascular density differences in advanced ovarian cancer after neoadjuvant chemotherapy with or without bevacizumab in real world

Our real-world study provides preliminary evidence that bevacizumab may confer differential prognostic benefits in AOC patients undergoing NAC followed by IDS, contingent upon tumor MVD quantified via CD34 immunohistochemistry, though it is important to acknowledge the lack of independent external validation for these findings. This potential biomarker-driven therapeutic heterogeneity preliminarily underscores the possibility of developing adaptive treatment algorithms that stratify patients based on angiogenic susceptibility profiles, which may lay a foundation for exploring precision administration of anti-VEGF therapy in a cost-effective paradigm.